期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

胃癌腹膜转移规范化治疗 被引量：2

Standardized treatment for peritoneal metastasis of gastric cancer
原文传递
导出
摘要 伴有腹膜转移的进展期胃癌,其存活率仍处于低谷状态,是进展期胃癌死亡的主要原因。全身化疗及腹腔内化疗是腹膜转移治疗的主要措施。新药的问世及诸多RCT研究的结果显示,根据腹膜转移的程度、阶段,合理选择治疗方案(化疗、手术),能够有效地提高伴有腹膜转移性进展期胃癌的治疗效果,改善病人的预后。 The survival rate of advanced gastric cancer with peritoneal metastasis is still in a low state. It is a major cause of death from advanced gastric cancer. Systemic chemotherapy and intraperitoneal chemotherapy are the main treatment measures of peritoneal metastasis. The introduction of new drugs and the study on many RCT showed that reasonable selection of treatment（chemotherapy, surgery） according to the degree of peritoneal metastasis and stage can improve the treatment effect and the prognosis of peritoneal metastasis of gastric cancer effectively.
作者 胡祥
机构地区 大连医科大学附属第一医院普通外科
出处 《中国实用外科杂志》 CSCD 北大核心 2014年第7期621-624,共4页 Chinese Journal of Practical Surgery
关键词 进展期胃癌 腹膜转移 化疗 手术治疗 advanced gastric cancer peritoneal metastasis chemotherapy surgery
分类号 R6 [医药卫生—外科学]
  • 相关文献

参考文献14

  • 1Cao L,Hu X,Zhang Y,et al.Ometal milk spots in screening gas-tric cancer stem cells[J].Neoplasma,2011,58(1):20-26.
  • 2Koizumi W,Narahara H,Nara T,et al.S-1 plus cisplatin versusS-1 alone for first-line treatment of advance gastric cancer(SPIRITS trial): a phase III trial[J]. Lancet Oncol,2008,9(3):215-221.
  • 3Fushida S,Kinoshita J,Kaji M,et al.PhaseⅠ/Ⅱ study of intraperitonealdocetaxel plus S-1 for the gastric cancer patients withperitoneal carcinomatosis[J].Can Chem Phar,2013,71(5):1265-1272.
  • 4Kuramoto M,Shimada S,Ikeshima S,et al.Extensive intraoperativeperitoneal lavage as a standard prophylactic strategy forperitoneal recurrence in patients with gastric carcinoma[J].AnnSurg,2009,250(2):242-246.
  • 5片山寛次,村上真,慶野靖夫,ほか.スキルス胃癌腹膜転移に対する温熱化學療法―安全かつ効果のなchemo hyperthermicperitoneal perfusion(CHPP)の手技[J].臨床外科,2006,61(6):755-762.
  • 6Fujimura T,Yonemura Y,Muraoka K,et al.Continuous hyperthermicperitoneal perfusion for the prevention of peritoneal recurrenceof gastric cancer : randomized controlled study[J].World Surg,1994,18(1):150-155.
  • 7Kunisaki C,Shimada H,Nomura M,et al.Lack of efficacy ofprophylactic continuous hyperthermic peritoneal perfusion onsabseguen peritoneal recurrence and survival in patients with advancedgastric cancer[J].Surgery,2002,131(5):521-528.
  • 8Yonemura Y,de Aretxabala X,Fujimura T,et al.Intraoperativechemohyperthermic peritoneal perfusion as an adjuvant to gastriccancer: final results of a randomized controlled study[J].Hepatogastroentelogy,2001,48(42):1776-1782.
  • 9Katayama K,Makimoto K,Maeda H,et al.Continyous hyperthermicperitoneal perfusion (HPP)-Thermal daze during CHPPand response to treatment[J].Hyperthermic Oncology in Japa’97.1997,111(7):50-53.
  • 10Yan TD,Black D,Sugarbakes PH,et al.A systematic reviewand meta analysis of the randomized controlled trials on adjuvantintraperitoneal chemotherapy for resectable gastric caner[J].Ann Surg Oncol,2007,14(10):2702-2713.

同被引文献24

  • 1Collins FS, Varmus H. A new initiative on precision medicine [ J ]. N Engl J Med, 2015,372(9):793-795.
  • 2Jameson JL, Longo DL. Precision medicine-personalized, prob- lematic, and promising [J]. N Engl J Med, 2015, 372(23): 2229-2234.
  • 3Network CGAR. Comprehensive molecular characterization of gastric adenocarcinoma[ J ]. Nature, 2014,513(7517):202-209.
  • 4Sun YS, Cui Y, Tang L, et al. Early evaluation of cancer re- sponse by a new functional biomarker: apparent diffusion coeffi- cient[J]. Am J Roent, 2011,197(1):23-29.
  • 5Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesopha- geal junction cancer (TOGA): a phase 3, open-label, randomised controlled trial[J]. Lancet, 2010,376(9742):687-697.
  • 6Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monothera- py for previously treated advanced gastric or gastro-oesophageal junction adenncarcinoma (REGARD): an international, ran- domised, muhicentre, placebo-controlled, phase 3 trial [J]. Lan- cet, 2014,383(9911):31-39.
  • 7Wilke H, Muro K, Van Cutsem E, et al. Ramucirumab plus pa- clitaxel versus placebo plus paclitaxel in patients with previ- ously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial[J]. Lancet Oneol, 2014,15(11):1224-1235.
  • 8Deng N, Goh LK, Wang H, et al. A comprehensive survey of ge- nomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets[J]. Gut, 2012,61(5):673-684.
  • 9Kuramoto M, Sh~mada S, Ikeshima S, et al. Extensive intraoper- ative peritoneal lavage as a standard prophylactic strategy for peritoneal recurrence in patients with gastric carcinoma [J]. Ann Surg, 2009,250(2):242-246.
  • 10Tsuburaya A, Mizusawa J, Tanaka Y, et al. Neoadjuvant chemo- therapy with S-1 and cisplatin followed by D2 gastrectomy with para-aortic lymph node dissection for gastric cancer with ex- tensive lymph node metastasis [Jl. Br J Surg, 2014,101(6): 653-660.

引证文献2

二级引证文献24

中国实用外科杂志
2014年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部